Ventyx Biosciences (VTYX) Stock Forecast & Price Target

Compare

580 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VTYX Analyst Ratings

Moderate Buy

3 Buy

2 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Ventyx

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VTYX Stock 12 Month Forecast

Average Price Target

$17.50

▲(617.21%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Ventyx Biosciences in the last 3 months. The average price target is $17.50 with a high forecast of $21.00 and a low forecast of $14.00. The average price target represents a 617.21% change from the last price of $2.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","22":"$22","5.5":"$5.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.5,11,16.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,3.4984615384615383,4.956923076923077,6.415384615384616,7.873846153846154,9.332307692307692,10.790769230769232,12.24923076923077,13.707692307692309,15.166153846153847,16.624615384615385,18.083076923076923,19.54153846153846,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,3.229230769230769,4.418461538461539,5.607692307692308,6.796923076923077,7.986153846153846,9.175384615384615,10.364615384615384,11.553846153846155,12.743076923076924,13.932307692307692,15.121538461538464,16.310769230769232,{"y":17.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.96,3.88,4.800000000000001,5.720000000000001,6.640000000000001,7.5600000000000005,8.48,9.4,10.32,11.240000000000002,12.16,13.080000000000002,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.59,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$21.00

Average Price Target$17.50

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen RahimiPiper Sandler

Piper Sandler

$21

Buy

760.66%

Upside

Reiterated

06/09/25

Piper Sandler Sticks to Their Buy Rating for Ventyx Biosciences (VTYX)

Sam SlutskyLifeSci Capital

LifeSci Capital

―

Buy

―

Reiterated

05/22/25

Ventyx Biosciences: Strategic Investment by Sanofi Highlights Promising Prospects and Innovative Approach

Vikram PurohitMorgan Stanley

Morgan Stanley

―

Hold

―

Reiterated

05/19/25

Morgan Stanley Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

Edward NashCanaccord Genuity

Canaccord Genuity

$14

Buy

473.77%

Upside

Reiterated

05/11/25

Ventyx Biosciences: Promising Pipeline and Upcoming Data Readouts Justify Buy Rating

Emily BodnarH.C. Wainwright

H.C. Wainwright

―

Hold

―

Reiterated

05/09/25

Ventyx Biosciences (VTYX) Gets a Hold from H.C. Wainwright

Derek ArchilaWells Fargo

Wells Fargo

$11

Buy

350.82%

Upside

Reiterated

02/27/25

Analysts' Top Healthcare Picks: Genfit (GNFTF), Ventyx Biosciences (VTYX)We think VTYX has several shots on goal to generate upside for shares in 2025, of which VTX2735's Ph2 data in recurrent pericarditis in 2H25 could be the most important. VTX2735's recurrent pericarditis results expected in 2H25. Recall, this study includes n=30 pts with a 6wk treatment period + 7wk extension. Endpoints include change in NRS pain score, hsCRP, and safety. Given the current treatment landscape in RP, we think an oral could be differentiated and, in terms of efficacy, something between colchicine and rilonacept would be competitive enough for the co to move this program fwd. We think this could be the biggest source of upside for shares in 2025.

Jeff JonesOppenheimer

Oppenheimer

$10→$9

Buy

268.85%

Upside

Reiterated

11/08/24

Ventyx Biosciences (VTYX) Gets a Buy from Oppenheimer

Michael YeeJefferies

Jefferies

$15

Buy

514.75%

Upside

Reiterated

09/23/24

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

Hold

-18.03%

Downside

Reiterated

08/13/24

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen RahimiPiper Sandler

Piper Sandler

$21

Buy

760.66%

Upside

Reiterated

06/09/25

Piper Sandler Sticks to Their Buy Rating for Ventyx Biosciences (VTYX)

Sam SlutskyLifeSci Capital

LifeSci Capital

―

Buy

―

Reiterated

05/22/25

Ventyx Biosciences: Strategic Investment by Sanofi Highlights Promising Prospects and Innovative Approach

Vikram PurohitMorgan Stanley

Morgan Stanley

―

Hold

―

Reiterated

05/19/25

Morgan Stanley Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

Edward NashCanaccord Genuity

Canaccord Genuity

$14

Buy

473.77%

Upside

Reiterated

05/11/25

Ventyx Biosciences: Promising Pipeline and Upcoming Data Readouts Justify Buy Rating

Emily BodnarH.C. Wainwright

H.C. Wainwright

―

Hold

―

Reiterated

05/09/25

Ventyx Biosciences (VTYX) Gets a Hold from H.C. Wainwright

Derek ArchilaWells Fargo

Wells Fargo

$11

Buy

350.82%

Upside

Reiterated

02/27/25

Jeff JonesOppenheimer

Oppenheimer

$10→$9

Buy

268.85%

Upside

Reiterated

11/08/24

Ventyx Biosciences (VTYX) Gets a Buy from Oppenheimer

Michael YeeJefferies

Jefferies

$15

Buy

514.75%

Upside

Reiterated

09/23/24

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

Hold

-18.03%

Downside

Reiterated

08/13/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ventyx Biosciences

1 Month

xxx

Success Rate

8/25 ratings generated profit

Average Return

-6.95%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 32.00% of your transactions generating a profit, with an average return of -6.95% per trade.

3 Months

xxx

Success Rate

8/25 ratings generated profit

Average Return

-14.76%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 32.00% of your transactions generating a profit, with an average return of -14.76% per trade.

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

9/25 ratings generated profit

Average Return

-7.28%

reiterated a buy rating 5 days ago

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 36.00% of your transactions generating a profit, with an average return of -7.28% per trade.

2 Years

xxx

Success Rate

5/23 ratings generated profit

Average Return

-51.20%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 21.74% of your transactions generating a profit, with an average return of -51.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VTYX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VTYX has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. VTYX average Analyst price target in the past 3 months is 17.50.

Each month's total comprises the sum of three months' worth of ratings.

VTYX Financial Forecast

VTYX Earnings Forecast

Next quarter’s earnings estimate for VTYX is -$0.46 with a range of -$0.57 to -$0.36. The previous quarter’s EPS was -$0.39. VTYX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year VTYX has Outperformed its overall industry.

No data currently available

VTYX Sales Forecast

Next quarter’s sales forecast for VTYX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VTYX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year VTYX has Preformed in-line its overall industry.

VTYX Stock Forecast FAQ

What is VTYX’s average 12-month price target, according to analysts?

Based on analyst ratings, Ventyx Biosciences’s 12-month average price target is 17.50.

What is VTYX’s upside potential, based on the analysts’ average price target?

Ventyx Biosciences has 617.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VTYX a Buy, Sell or Hold?

Ventyx Biosciences has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.

What is Ventyx Biosciences’s price target?

The average price target for Ventyx Biosciences is 17.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $14.00. The average price target represents 617.21% Increase from the current price of $2.44.

What do analysts say about Ventyx Biosciences?

Ventyx Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of VTYX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ventyx Biosciences (VTYX) Stock Forecast & Price Target

VTYX Analyst Ratings

VTYX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ventyx Biosciences

VTYX Analyst Recommendation Trends

VTYX Financial Forecast

VTYX Earnings Forecast

VTYX Sales Forecast

VTYX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts